Gyros completes five new sales of its Gyrolab™ protein quantification platform
Gyros announced today that it has completed the separate sales of five Gyrolab™ microfluidic system platforms to Merck, Biogen-Idec and a third, unnamed company, all in the USA, and to NovImmune and Serono in Europe.
Gyros microfluidic platform consists of Gyrolab Bioaffy™compact disk (CD) microlaboratories (facilitating miniaturized and integrated protein quantification applications) and Gyrolab Workstation (a fully automated system for running Gyrolab Bioaffy CDs). Together they provide a simple to use, precisely controlled solution for processing hundreds of samples in parallel at nanoliter scale. Scientists are able to use immunoassays with a very broad measurement range to generate more information from less sample, improving both productivity and efficiency.
Commenting on the recent sales, Gyros CEO, Jan Würtz, said, “2006 was a successful year for Gyros. Following sales earlier in 2006 to CAT and AstraZeneca, these five new sales mean that we are really starting to extend our customer base. We will be looking to continue this trend through 2007, as more and more companies recognize that our microfluidic technology can provide them with significant advantages over traditional methods, like ELISA.”
For Gyros AB
Katie Odgaard / Lorna Cuddon
Zyme Communications Ltd
Tel: +44 (0) 7787 502 947 / +44 (0) 7811 996 942
Skype: kodgaard / lorna.cuddon
Email: email@example.com / firstname.lastname@example.org
Notes to editors:
About Gyros (www.gyros.com)
Gyros AB is the world leader in utilization of microfluidic technologies to miniaturize and automate immunoassays. The GyrosTM immunoassay platform increases productivity and efficiency during development of biotherapeutics and vaccines, saving time and labor. Major biopharmaceutical companies and their service providers utilize the Gyros platform to boost time-critical workflows and meet increasing regulatory demands.
Spanning the entire spectrum of immunoassays, the platform cuts the time to result significantly. Faster development times, and unattended running of assays at nano-liter scale, save labor and sample. The ease of assay transfer between sites and from development to regulated environments is unsurpassed in the industry.
The company is based in Uppsala, Sweden and has regional sales and support offices in the USA and Europe, and a growing network of distributors.